543 related articles for article (PubMed ID: 22957857)
1. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.
Ivachtchenko AV; Ivanenkov YA; Skorenko AV
Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857
[TBL] [Abstract][Full Text] [Related]
2. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives.
Ivachtchenko AV; Ivanenkov YA
Expert Opin Ther Pat; 2012 Aug; 22(8):917-64. PubMed ID: 22816965
[TBL] [Abstract][Full Text] [Related]
3. 5-HT(7) receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009).
Leopoldo M; Lacivita E; Berardi F; Perrone R
Expert Opin Ther Pat; 2010 Jun; 20(6):739-54. PubMed ID: 20476847
[TBL] [Abstract][Full Text] [Related]
4. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
Holenz J; Pauwels PJ; Díaz JL; Mercè R; Codony X; Buschmann H
Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
[TBL] [Abstract][Full Text] [Related]
5. 5-hydroxytryptamine subtype 6 receptor modulators: a patent survey.
Ivachtchenko AV; Ivanenkov YA; Tkachenko SE
Expert Opin Ther Pat; 2010 Sep; 20(9):1171-96. PubMed ID: 20716023
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic potential of 5-HT1A receptors: a patent review.
Lacivita E; Di Pilato P; De Giorgio P; Colabufo NA; Berardi F; Perrone R; Leopoldo M
Expert Opin Ther Pat; 2012 Aug; 22(8):887-902. PubMed ID: 22788968
[TBL] [Abstract][Full Text] [Related]
7. Serotonergic 5-HT6 Receptor Antagonists: Heterocyclic Chemistry and Potential Therapeutic Significance.
Bali A; Singh S
Curr Top Med Chem; 2015; 15(17):1643-62. PubMed ID: 25915615
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
9. Computational approaches to the design of novel 5-HT6 R ligands.
Ivanenkov YA; Majouga AG; Veselov MS; Chufarova NV; Baranovsky SS; Filkov GI
Rev Neurosci; 2014; 25(3):451-67. PubMed ID: 24867282
[TBL] [Abstract][Full Text] [Related]
10. Discovery of aryl-biphenyl-2-ylmethylpiperazines as novel scaffolds for 5-HT(7) ligands and role of the aromatic substituents in binding to the target receptor.
Kim Y; Kim J; Tae J; Roth BL; Rhim H; Keum G; Nam G; Choo H
Bioorg Med Chem; 2013 May; 21(9):2568-76. PubMed ID: 23541835
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of 5-HT6 Receptor Agonists.
Karila D; Freret T; Bouet V; Boulouard M; Dallemagne P; Rochais C
J Med Chem; 2015 Oct; 58(20):7901-12. PubMed ID: 26099069
[TBL] [Abstract][Full Text] [Related]
12. N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.
van Loevezijn A; Venhorst J; Iwema Bakker WI; de Korte CG; de Looff W; Verhoog S; van Wees JW; van Hoeve M; van de Woestijne RP; van der Neut MA; Borst AJ; van Dongen MJ; de Bruin NM; Keizer HG; Kruse CG
J Med Chem; 2011 Oct; 54(20):7030-54. PubMed ID: 21866910
[TBL] [Abstract][Full Text] [Related]
13. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
Holenz J; Mercè R; Díaz JL; Guitart X; Codony X; Dordal A; Romero G; Torrens A; Mas J; Andaluz B; Hernández S; Monroy X; Sánchez E; Hernández E; Pérez R; Cubí R; Sanfeliu O; Buschmann H
J Med Chem; 2005 Mar; 48(6):1781-95. PubMed ID: 15771424
[TBL] [Abstract][Full Text] [Related]
14. Phenylpiperazine derivatives: a patent review (2006 - present).
Maia Rdo C; Tesch R; Fraga CA
Expert Opin Ther Pat; 2012 Oct; 22(10):1169-78. PubMed ID: 22957817
[TBL] [Abstract][Full Text] [Related]
15. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
[TBL] [Abstract][Full Text] [Related]
16. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
Terry AV; Buccafusco JJ; Wilson C
Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
[TBL] [Abstract][Full Text] [Related]
17. Anti-Alzheimer's multitarget-directed ligands with serotonin 5-HT
Marcinkowska M; Bucki A; Panek D; Siwek A; Fajkis N; Bednarski M; Zygmunt M; Godyń J; Del Rio Valdivieso A; Kotańska M; Kołaczkowski M; Więckowska A
Arch Pharm (Weinheim); 2019 Jul; 352(7):e1900041. PubMed ID: 31162703
[TBL] [Abstract][Full Text] [Related]
18. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
Holmberg P; Sohn D; Leideborg R; Caldirola P; Zlatoidsky P; Hanson S; Mohell N; Rosqvist S; Nordvall G; Johansson AM; Johansson R
J Med Chem; 2004 Jul; 47(16):3927-30. PubMed ID: 15267230
[TBL] [Abstract][Full Text] [Related]
19. Novel M(1) allosteric ligands: a patent review.
Kuduk SD; Beshore DC
Expert Opin Ther Pat; 2012 Dec; 22(12):1385-98. PubMed ID: 23092292
[TBL] [Abstract][Full Text] [Related]
20. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
